Semaglutide is an FDA-approved injectable medication administered once a week to aid in weight management for overweight and obese adults with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. Unlike other weight loss methods, semaglutide stands out as a groundbreaking medication containing glucagon-like peptide-1. Initially approved under the brand name Ozempic ® for controlling blood sugar levels in diabetic patients, it has now gained approval for weight loss purposes. WeGovy ® is the trademark name for the injectable pen for weightloss for adults with obesity. While there is much enthusiasm surrounding this newly approved weight loss treatment, semaglutide is most suitable for individuals with a BMI of at least 30. Optimal results are achieved when the treatment is combined with a reduced-calorie diet and regular exercise. Clinical trials have shown that, on average, patients lost 15 percent of their body weight, translating to a potential loss of up to 20 pounds per month. However, these results are further enhanced when complemented by a healthy lifestyle and regular exercise habits.

Tirzepatide is an FDA-approved medication used for treating type 2 diabetes and has recently been approved by the FDA for treating weight loss. Administered once a week via injection, tirzepatide is marketed under the brand name Mounjaro® for diabetes and Zepbound® for weightloss. Both semaglutide and tirzepatide work to reduce food intake and increase insulin sensitivity. However, tirzepatide's dual action, targeting both GLP-1 and glucagon receptors, distinguishes it from semaglutide, which solely acts as a GLP-1 receptor agonist.